Prognostic and Therapeutic Implications of Molecular Genotype in Advanced Thyroid Cancer

Lori Wirth, MD, explains how molecular profiling in advanced differentiated thyroid cancer informs both treatment selection and prognosis. Identifying actionable genomic alterations enables clinicians to tailor systemic therapy based on tumor genotype, a cornerstone of precision oncology. Beyond guiding therapy, specific molecular patterns also provide prognostic insight. For example, while the BRAF V600E mutation is common in papillary thyroid cancer, the presence of co-mutations—such as TERT promoter alterations alongside BRAF V600E—is associated with more aggressive disease biology and poorer outcomes compared with BRAF-mutant tumors alone. These combined genomic alterations can influence disease progression and clinical decision-making. Integrating comprehensive molecular testing into routine evaluation allows clinicians not only to optimize targeted treatment strategies but also to better stratify risk and counsel patients regarding expected disease course.

Supported in part by Eisai, content independently produced by OncLive.